Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: Current perspectives

Journal of Blood Medicine

Volumn 7, Issue , 2016, Pages 159-169

  Bayanzay, Karim ^a   Alzoebie, Lama ^a  

^a GULF MEDICAL UNIVERSITY   (United Arab Emirates)

Author keywords

Chelators; Deferiprone; Deferiserox; Deferoxamine; Hematology; Hepatic iron storage; Iron chelation therapy; Iron overload; Liver iron concentration; Serum ferritin concentration

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; HEMOGLOBIN F;

ABDOMINAL DISCOMFORT; AGRANULOCYTOSIS; ALPHA THALASSEMIA; ARTHRALGIA; ARTHRITIS; BETA THALASSEMIA INTERMEDIA; BETA THALASSEMIA MINOR; BLOOD TRANSFUSION; CAUSE OF DEATH; CHELATION THERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; EYE TOXICITY; HEART DISEASE; HUMAN; IRON BLOOD LEVEL; IRON CHELATION; IRON OVERLOAD; LIVER BIOPSY; LOCAL SKIN REACTION; LUNG TOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OTOTOXICITY; PATHOGENESIS; RASH; REVIEW; SPLENECTOMY; SURVIVAL; THALASSEMIA; THALASSEMIA MAJOR;

EID: 85006165325     PISSN: None     EISSN: 11792736     Source Type: Journal    
DOI: 10.2147/JBM.S61540     Document Type: Review

References (61)

1. Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of β thalassaemia intermedia. Br J Haematol. 2011;152(5): 512–523.
2. Taher AT, Viprakasit V, Musallam KM, Cappellini MD. Treating iron overload in patients with non-transfusion-dependent thalassemia. Am J Hematol. 2013;88(5):409–415.
3. Ladis V, Berdousi H, Gotsis E, Kattamis A. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol. 2010;151(5):504–508.
4. Tony S, Daar S, Elshinawy M, Al-Zadjaly S, Al-Khabori M, Wali Y. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores. Pediatr Hematol Oncol. 2012;29(6):579–584.
5. Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood. 2003;101(3):791–800.
6. Musallam KM, Rivella S, Vichinsky E, Rachmilewitz EA. Non-transfusion-dependent thalassemias. Haematologica. 2013;98(6):833–844.
7. Qari MH, Wali Y, Albagshi MH, et al. Regional consensus opinion for the management of Beta thalassemia major in the Arabian Gulf area. Orphanet J Rare Dis. 2013;8:143.
8. Northern California Comprehensive Thalassemia Center. Standard-of-Care Clinical Practice Guidelines (2012). Available from: http:// thalassemia.com/treatment-guidelines-4.aspx#gsc.tab=0. Accessed June 27, 2016.
9. Prabhu R, Prabhu V, Prabhu RS. Iron overload in beta thalassemia: a review. J Biosci Tech. 2009;1(1):20–31.
10. Wood JC. Magnetic resonance imaging measurement of iron overload. Curr Opin Hematol. 2007;14(3):183–190.
11. Wood JC. Diagnosis and management of transfusion iron overload: the role of imaging. Am J Hematol. 2007;82(12 Suppl):1132–1135.
12. Sheth S. SQUID biosusceptometry in the measurement of hepatic iron. Pediatr Radiol. 2003;3(6):373–377.
13. Chapman RW, Williams G, Bydder G, Dick R, Sherlock S, Kreel L. Computed tomography for determining liver iron content in primary haemochromatosis. Br Med J. 1980;280(6212):440–442.
14. Bhat AA, Parwani RN, Wanjari SP. Demonstration of iron in exfoliated buccal cells of β-thalassemia major patients. J Cytol. 2013;30(3): 169–173.
15. Bacon BR, Britton RS. The pathology of hepatic iron overload: a free radical-mediated process. Hepatology. 1990;11(1):127–137.
16. Engle MA, Erlandson M, Smith CH. Late cardiac complications of chronic, severe, refractory anemia with hemochromatosis. Circulation. 1964;30:698–705.
17. Grundy RG, Woods KA, Savage MO, Evans JP. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch Dis Child. 1994;71(2):128–132.
18. Kwan EY, Lee AC, Li AM, et al. A cross-sectional study of growth, puberty and endocrine function in patients with thalassaemia major in Hong Kong. J Paediatr Child Health. 1995;31(2):83–87.
19. De Sanctis V. Growth and puberty and its management in thalassemia. Horm Res. 2002;58 Suppl 1:72–79.
20. Barry M, Flynn DM, Letsky EA, Risdon RA. Long-term chelation therapy in thalassaemia major: effect on liver iron concentration, liver histology, and clinical progress. Br Med J. 1974;2(5909):16–20.
21. Brittenham GM, Griffith PM, Nienhuis AW, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med. 1994;331(9):567–573.
22. Bronspiegel-Weintrob N, Olivieri NF, Tyler B, Andrews DF, Freedman MH, Holland FJ. Effect of age at the start of iron chelation therapy on gonadal function in β-thalassemia major. N Engl J Med. 1990;323(11):713–719.
23. Olivieri NF, Nathan DG, McMillan JH, et al. Survival in medically treated patient with homozygous β-thalassemia. N Engl J Med. 1994;331(9):574–578.
24. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haemotologica. 2004;89(10):1187–1193.
25. De Virgiliis S, Cossu P, Sanna G, et al. Iron chelation in transfusiondependent thalassemia with chronic hepatitis. Acta Haematol. 1982; 67(1):49–56.
26. Smith RS. Iron excretion in thalassaemia major after administration of chelating agents. Br Med J. 1962;2(5319):1577–1580.
27. Schafer AI, Rabinowe S, Le Boff MS, Bridges K, Cheron RG, Dluhy R. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload. Arch Intern Med. 1985;145(7): 1217–1221.
28. Davis BA, Porter JB. Long-term outcome of continuous 24-hour deferoxamine infusion via indwelling intravenous catheters in high-risk β-thalassemia. Blood. 2000;95(4):1229–1236.
29. Delea TE, Edelsberg J, Sofrygin O, et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion. 2007;47(10):1919–1929.
30. De Virgillis S, Congia M, Frau F, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr. 1988;113(4): 661–669.
31. Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood. 2011;118(13):3479–3488.
32. Cunningham MJ, Macklin EA, Neufield EJ, Cohn AR. Thalassemia Clinical Research Network. Complications of beta-thalassemia major in North America. Blood. 2004;104(1):34–39.
33. Porter JB, Jaswon MS, Huehns ER, East CA, Hazell JW. Desferrioxamine ototoxicity: evaluation of risk factors in thalassaemic patients and guidelines for safe dosage. Br J Haematol. 1989;73(3):403–409.
34. Olivieri NF, Buncic JR, Chew E, et al. Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions. N Engl J Med. 1986;314(14):869–873.
35. Yacobovich J, Stark P, Barzilai-Birenbaum S, et al. Acquired proximal renal tubular dysfunction in β-thalassemia patients treated with deferasirox. J Pediatr Hematol Oncol. 2010;32(7):564–567.
36. Piga A, Roggero S, Salussolia I, Massano D, Serra M, Longo F. Deferiprone. Ann N Y Acad Sci. 2010;1202:75–78.
37. Cappellini MD, Musallam KM, Taher AT. Overview of iron chelation therapy with desferrioxamine and deferiprone. Hemoglobin. 2009;33 Suppl 1:S58–S69.
38. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine-or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–3737.
39. Mamtani M, Kulkarni H. Influence of iron chelators on myocardial iron and cardiac function in transfusion-dependent thalassaemia: a systematic review and meta-analysis. Br J Haematol. 2008;141(6):882–890.
40. Anderson LJ, Westwood MA, Holden S, et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br J Haematol. 2004;127(3):348–355.
41. Hoffbrand AV, Cohen A, Hershko C. Role of deferiprone in chelation therapy for transfusional iron overload. Blood. 2003;102(1):17–24.
42. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol. 2000;108(2):305–312.
43. Olivieri NF, Brittenham GM, McLaren CE, et al. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. N Engl J Med. 1998;339(7):417–423.
44. Pippard MJ, Weatherall DJ. Oral iron chelation therapy for thalassaemia: an uncertain scene. Br J Haematol. 2000;111(1):2–5.
45. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation. 2007;115(14):1876–1884.
46. Fisher SA, Brunskill SJ, Doree C, Chowdhury O, Gooding S, Roberts DJ. Oral deferiprone for iron chelation in people with thalassaemia. Cochrane Database Syst Rev. 2013;(8):CD004839.
47. Cappellini MD, Cohen A, Piga A, et al. A Phase 3 study of deferasirox (ICL670), a once daily iron chelator, in patients with beta-thalassemia. Blood. 2005;107(9):3455–3462.
48. Pennell DJ, Porter JB, Piga A, et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA). Blood. 2014;123(10):1447–1454.
49. Glickstein H, El RB, Shvartsman M, Cabantchik ZI. Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells. Blood. 2005;106(9):3242–3250.
50. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood. 2006;107(9):3733–3737.
51. US Food and Drug Administration [homepage on the Internet]. Exjade (deferasirox): Boxed Warning. FDA Safety Alerts for Human Medical Products; 2010. Available from: http://www.fda.gov/Safety/Med-Watch/%20SafetyInformation/SafetyAlertsforHumanMedicalProducts/ ucm200850.htm. Accessed June 28, 2016.
52. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol. 1998;103(2):361–364.
53. De Domenico I, Ward DM, Kaplan J. Specific iron chelators determine the route of ferritin degradation. Blood. 2009;114(20):4546–4551.
54. Hoffbrand AV, Taher A, Cappellini MD. How I treat transfusional iron overload. Blood. 2012; 120(18):3657–3669.
55. Olivieri NF, Berriman AM, Tyler BJ, Davis SA, Francombe WH, Liu PP. Continuous intravenous administration of deferoxamine in adults with severe iron overload. Am J Hematol. 1992;41(1):61–63.
56. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci. 2005;1054:445–450.
57. Roudbari M, Soltani-Rad M, Roudbari S. The survival analysis of beta thalassemia major patients in South East of Iran. Saudi Med J. 2008;29(7):1031–1035.
58. Ehlers KH, Giardina PJ, Lesser ML, Engle MA, Hilgartner MW. Prolonged survival in patients with beta-thalassemia major treated with deferoxamine. J Pediatr. 1991;118(4 Pt 1):540–545.
59. Fosburg M, Nathan DG. Treatment of Cooley’s anemia. Blood. 1990;76(3):435–444.
60. Loukopoulos D, Voskaridou E, Stamoulakatou A, et al. Hydroxyurea therapy in thalassemia. Ann N Y Acad Sci. 1998;850:120–128.
61. Italia KY, Jijina FF, Merchant R, et al. Effect of hydroxyurea on the transfusion requirements in patients with severe HbE-beta-thalassae-mia: a genotypic and phenotypic study. J Clin Pathol. 2010;63(2): 147–150.